How did R&D and SG&A expenses change, and why?

Research and Development expenses increased by 13.8% to support pipeline programs and new product launches, such as Humira. Selling, General, and Administrative (SG&A) expenses rose by 11.7% due to increased marketing and sales support for new and existing products, including accelerated spending for the Humira launch.

What is the status of Abbott's restructuring efforts?

Abbott announced restructuring plans in October 2002 to align global manufacturing operations and improve efficiencies in its Diagnostics and International segments. As of March 31, 2003, a significant portion of the initially accrued charges related to employee costs have been paid, with $68 million remaining accrued for these plans.

What are the key legal and regulatory issues facing Abbott?

Abbott is involved in several legal proceedings, including antitrust suits related to pharmaceutical pricing and patent settlements, investigations into its enteral nutritional business, and issues with its diagnostics manufacturing operations subject to an FDA consent decree. While management believes most of these will not materially affect the company, the enteral nutritional investigation carries a risk of material impact on cash flows and operations.

ABT 10-Q Quarterly Report Q1 FY2003 — Revenue, Net Income, EPS

Q: What was the primary driver of Abbott's sales growth in the first quarter of 2003?

Abbott's net sales grew by 9.3% to $4.58 billion, driven by strong performance across most segments, particularly Pharmaceuticals and International. This growth was supported by overall unit increases and the favorable impact of a weaker U.S. dollar.

Summary

Abbott Laboratories reported a 9.3% increase in net sales for the first quarter of 2003, reaching $4.58 billion, compared to $4.19 billion in the prior year. This growth was driven by strong performance across most segments, particularly Pharmaceuticals and International, with overall sales benefiting from unit growth and the weaker U.S. dollar. Despite a rise in operating expenses, including R&D and SG&A, the company managed to slightly reduce its net earnings to $801 million from $854 million in the prior year, resulting in a decrease in diluted EPS to $0.51 from $0.54. Key areas of focus for investors include the company's ongoing restructuring efforts aimed at efficiency improvements and the significant increase in Research and Development spending to support pipeline programs, notably for Humira. While the company faces various litigation and investigations, management believes the ultimate disposition of these matters will not materially affect its financial position, with the exception of the enteral nutritional investigation. Abbott's liquidity remains strong, supported by robust operating cash flow and significant credit facilities, and the company continues its share repurchase program.

Key Highlights

1Net sales increased by 9.3% to $4.58 billion for the first quarter of 2003, up from $4.19 billion in the prior year.
2Diluted Earnings Per Share (EPS) decreased slightly to $0.51 from $0.54 year-over-year.
3Research and Development expenses increased by 13.8% to support pipeline programs and new product launches like Humira.
4Selling, General, and Administrative (SG&A) expenses rose by 11.7%, primarily due to increased marketing support for new and existing products.
5Gross profit margin declined to 52.0% from 54.7%, attributed to unfavorable product mix, exchange rates, and higher manufacturing costs.
6Abbott Laboratories is actively engaged in restructuring plans to improve operational efficiencies, particularly in the Diagnostics and International segments.
7The company reported significant legal and environmental matters, including ongoing investigations and litigation, with management estimating reserves of approximately $150 million, excluding the enteral nutritional investigation.

ABBOTT LABORATORIES Quarterly Report for Q1 Ended Mar 31, 2003

Summary

Key Highlights

Frequently Asked Questions